MENU
 

PRE TAX NTA |$3.53

Value as at close of business on 7 March 2025

Why Chris Kourtis just bought CSL and ResMed

A true contrarian investor, Chris Kourtis can find himself sounding a lot like a bull when in the company of bears, and there’s a lot to be bearish about at the moment. 

“When you put it in the melting pot very slow global growth, very high and sticky stagflation against a backdrop of the geopolitical environment, it’s a time to be cautious,” he tells The Australian Financial Review.

“A lot of people I speak to are pretty bearish, and it worries me because when everyone is bearish, that’s when the market will surprise you.”

With more than three decades managing Australian equity funds behind him, the famed stock picker has seen his share of market shake-ups. 

“It’s fair to say, I’ve probably negotiated every market cycle or geopolitical event you can think of, with the exception of the Great Depression and the Vietnam War,” says the funds management Hall of Famer, who will reveal one of his latest stock picks at the upcoming Sohn Hearts & Minds event in Sydney, next week.

Kourtis left his own boutique firm Portfolio Partners in 2003 to start up with Ellerston Capital, where he’s spent the past two decades, which was initially established by the Packer family.

There, he’s developed his reputation for going against the market – but that hasn’t stopped him picking up a few well-known names more recently.

“Whether you’re a value manager or a growth manager or a quant, I guarantee there are certain names that everyone owns – we don’t own a lot of those names,” he says.

“But there are a couple I’ve invested in recently that have been smoked – absolutely pulverised – and we’re happy to now be long on a couple of those,” he adds.

 

Ozempic panic overdone

New additions include health tech giant CSL, which Kourtis says he hasn’t owned in some time, opting so stay on the sidelines until this month. 

In fact, not owning the biotech during its recent sell-off was one of the fund’s smartest more recent plays, successfully avoiding a 7 per cent decline in September alone, according to the fund’s latest report.

However, with prices now down more than 20 per cent in the past six months, Kourtis says CSL is simply too cheap to not pick up, given its fundamentals.

“Back in July and I said CSL was an expensive defensive,” he says.

“But now for the first time in a long time, it’s no longer an expensive defensive. It’s screening really cheap.”

Another new addition is ResMed, which like CSL, sank further last month after the rise of weight-loss drugs like Ozempic sparked concerns over the companies’ key revenue markets.

“[ResMed] is in the CSL camp. It’s no longer an expensive defensive. It’s now become an oversold, cheap defensive. The market has got it wrong.”

Unperturbed by the Ozempic acolytes, Kourtis likens the Ozempic panic hitting healthcare companies such as CSL and ResMed to the sell-off that hurt Harvey Norman shares in the lead up to Amazon’s launch in Australia back in 2017.

“People were acting like JB Hi-Fi was never going to sell another flat screen again,” he says. “That stock was at $22. In two years it was $50. How can the market get it 100 per cent wrong? It happens all the time.”

Kourtis is no stranger to making unpopular buys and isn’t afraid of doubling down when the market disagrees.

“I love buying bombed out names. Sometimes you catch a falling knife but if your investment thesis holds true, and it’s oversold for the wrong reason ... you strengthen the position,” he says.

“If you get it wrong, you just have to wear it – that’s life in the big city.”

And over his four decades in the industry, Kourtis has honed his talent for picking oversold stocks against the backdrop of some of the worst market crashes of the past century.

“I was on the trading floor when the equity market crashed in October ’87,” he recalls. “I walked in one day and suddenly the market’s down 25 per cent. That was a bit of a shock to a young upstart.”

But even after several boom-bust cycles, including a once-in-a-century pandemic, Kourtis says nothing was more humbling than the global financial crisis of 2008.

“We were on the precipice and just about to go over the cliff into the abyss. A lot of the institutions that are very highly regarded today, were on the edge of disappearing,” he says.

“I thought that could be the end of the capitalist system.”

That kind of experience means Kourtis’ major bets often look different from his peers’. Ellerston’s Australian Share Fund commonly holds index heavyweights like BHP and Santos alongside big holdings in relative minnows like Insignia Financial.

“Insignia is one of the cheapest financials in the world. I will go blue in the face buying that stock every day,” he adds.

 

‘Long and wrong’

True to his guns, Kourtis is sticking by the stock, despite the already embattled wealth giant falling 12 per cent in October alone, following news chief executive Renato Mota will leave the business in February.

“We’re long and wrong at the moment, but I’ll stand by my statement: that is a cheap stock. It should be $5, not $2.06,” Kourtis says.

“The company has borne the pain, and it’s now time to milk the cow, but the market is not rewarding because it’s had negative momentum.”

And it’s these kinds of momentum trading trends that Kourtis thinks has much of the market mis-priced at the moment.

“I’m all about buying the long and not having the time horizon of a gnat, which is what the market has currently,” he says.

“There’s always day traders running amok, but I’m taking a 30-year view. I think a lot of these guys take a 30-second view.”

And with that decades-long perspective behind him, Kourtis appears in his element in the current environment, hunting through the discard pile for mis-priced gems.

“I’m happy to be long a few of the names we’ve recently picked up. And if we’re wrong from here, then we’ll all go off the cliff together – but again, that’s life in the big city.”

Chris Kourtis will speak at Sohn Hearts & Minds at the Sydney Opera House on November 17. All profits will support Australian medical research organisations. The Australian Financial Review is a media partner for sohnheartsandminds.com.au

This article was originally posted by The Australian Financial Review here.

Licensed by Copyright Agency. You must not copy this work without permission.

Recent Posts

Read the latest insights
A curated list of HM1 investor updates, portfolio news and other interesting articles.
Read More
Reporting Season Insights: HM1 Core Portfolio Holdings
We spoke to our dedicated fund managers for an update on some of our major portfolio holdings following reporting season.
The investing megatrends you can’t ignore (and some you should rethink)
James Marlay of Livewire sat down with Vihari Ross of Antipodes (HM1 Conference Fund Manager) and James Tsinidis of Munro Partners (HM1 Core Fund Manager) to discuss the biggest megatrends shaping the future.
2025: Where to Find Market Opportunities
There are opportunities abound for investors with an active management mindset in 2025. Get more insights from one of HM1's Core Fund managers, Magellan.
Significant increase in profit and increased fully franked dividend
We're pleased to declare an increased half-year fully franked dividend of 8.0 cents per share payable in April 2025.
 

Reporting Season Insights: HM1 Core Portfolio Holdings

We spoke to our dedicated fund managers for an update on some of our major portfolio holdings following reporting season.

Read More
March 10th, 2025
 

The investing megatrends you can’t ignore (and some you should rethink)

James Marlay of Livewire sat down with Vihari Ross of Antipodes (HM1 Conference Fund Manager) and James Tsinidis of Munro Partners (HM1 Core Fund Manager) to discuss the biggest megatrends shaping the future.

Read More
March 3rd, 2025
 

2025: Where to Find Market Opportunities

There are opportunities abound for investors with an active management mindset in 2025. Get more insights from one of HM1's Core Fund managers, Magellan.

Read More
February 25th, 2025
 

Significant increase in profit and increased fully franked dividend

We're pleased to declare an increased half-year fully franked dividend of 8.0 cents per share payable in April 2025.

Read More
February 20th, 2025
 

Magellan's Elisa Di Marco - 3 Trends That Will Define The Next Decade

Elisa Di Marco of Magellan (HM1 Core Fund Manager) joined Equity Mates to unpack 3 big megatrends shaping our world today (and how we can invest in them).

Read More
February 7th, 2025
 

Nine top stock picks to prepare your portfolio for 2025

Health care, ride-sharing, and the emerging world of YouTube entertainers are among the industries leading investors have picked for growth in 2025.

Read More
January 21st, 2025
 

Resources fundies reveal top picks ahead of ‘stellar’ 2025

Some of Australia’s biggest resources funds are gearing up for a bumper start to the new year.

Read More
January 6th, 2025
 

Qiao Ma: finding killer companies, surviving the GFC & why founders win

Qiao Ma, Portfolio Manager of the Munro Partners joins Owen Rask on The Australian Investors Podcast.

Read More
January 6th, 2025
 

10 top fund managers reveal their long-term stock picks

With valuations stretched and geopolitical tensions high, the new year offers plenty of potholes for investors. 

Read More
December 28th, 2024
 

Rikki Bannan – Don’t get caught up in momentum

Conference Fund Manager Rikki Bannan, Executive Director at IFM Investors, joins Equity Mates to discuss her standout 2023 stock pick, Telix, and explore what opportunities lie ahead.

Read More
December 19th, 2024
 

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
December 10th, 2024
 

Nick Griffin – The Nvidia story is not over

Nick Griffin, Founding Partner & Chief Investment Officer of Munro Partners joined the Equity Mates podcast in their Summer Series.

Read More
December 9th, 2024
 

HM1 CEO Succession

Hearts and Minds Investments Limited advises that Paul Rayson intends to retire from the position of Chief Executive Officer, effective 19 February 2025.

Read More
December 5th, 2024
 

How Trump will impact equity markets

The United States has spoken. President Trump has returned to the White House. But how can we cut through the noise to reveal the investment, economic and geopolitical ramifications?

Read More
November 26th, 2024
 

Trump unifies top investors in decade-long bullish outlook for US

Nick Moakes, CIO of the $72 billion Wellcome Trust, told the conference that too many investors were banking on a return to the ultra-low interest rates that prevailed over the past decade.

Read More
November 20th, 2024
 

These rock-star stock picks could get markets talking next year

Eleven rock stars of international and local funds management took to stage – each tasked with picking and pitching one company whose shares will take off over the next year.

Read More
November 18th, 2024
 

Is anyone brave or stupid enough to bet against America?

Stock pickers have been punished for betting against the US. The choice between consensus and contrarianism on American exceptionalism is now harder than ever.

Read More
November 17th, 2024
 

Sohn: NYSE-listed Estee Lauder’s Northcape Capital pick

Northcape Capital’s Fleur Wright this gives a rare opportunity to buy a high quality company at an attractive price.

Read More
November 15th, 2024
 

Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Read More
November 15th, 2024
 

AI start-ups a threat to incumbent big companies

Paul Bassat predicts emerging artificial intelligence companies will disrupt sectors and overtake established incumbent companies just as rapidly as the seismic shifts that took place when the internet emerged in the mid-1990s.

Read More
November 15th, 2024
 

Howard Marks and Sohn’s big stars reveal seven rules for investing

Among the stock picks and stunts at the Sohh Hearts & Minds event, Howard Marks and Nick Moakes provided investors with long-term rules for playing markets.

Read More
November 15th, 2024
 

Sohn investors position for bullish but bumpy Trump ride

Australia and the rest of the world must adjust to a new Trump presidency that will deliver an expected bull market but also disruption, with the leader in waiting prepared to “create pain” to get his way.

Read More
November 15th, 2024
 

Sohn stock picker experts name best shares to invest in for year ahead

‍Don’t overlook down and out silver miners, legacy skincare brands ready for a revival and a big financial company suffering from a severe case of shareholder wealth destruction.

Read More
November 15th, 2024
 

Eleven stock tips from Sohn to get you through 2025

“There’s no finer place for the finance festival than in the festival city,” said Matthew Grounds. He, along with fellow Barrenjoey co-executive chairman Guy Fowler and investor Gary Weiss, is one of Sohn’s driving forces.

Read More
November 15th, 2024
 

Sohn Hearts & Minds Investments fund targets $1.5bn valuation

‍Hearts & Minds Investments chair Chris Cuffe is hoping for HM1 to grow to more than $1.5bn in the next five years.

Read More
November 14th, 2024
 

Galaxy Digital CEO Mike Novogratz believes bitcoin will hit $US100k

Bitcoin’s bounce to record highs in recent days is only the beginning of a fresh surge higher for cryptocurrency, says US billionaire Mike Novogratz.

Read More
November 9th, 2024
 

Why this New York hedge fund manager sees opportunity in European stocks

Influential New York-hedge fund manager Ricky Sandler will turn to Europe for his next stock pick.

Read More
November 6th, 2024
 

Antipodes’ Ross says short-term wealth hinges on US election

The portfolio manager says defensive stocks pose a bigger risk than the magnificent seven for investors that are overexposed to the American sharemarket.

Read More
November 5th, 2024
 

Concentration risk key for investors: Antipodes Partners’ Vihari Ross

The concentration risk in global stock indexes that has built up during the strong rise over the past year must now be a key consideration for global investors, according to Vihari Ross.

Read More
November 5th, 2024
 

The fundie betting big on China – with help from AI

Mr Mehta is sticking to his well-worn strategy: he’s hunting for companies across Asia that aren’t battling intense competition and have management teams focused on costs, cash generation and high payouts to shareholders.

Read More
November 5th, 2024